CN102083471B - 用于炎症成像的混合配体核/壳氧化铁纳米颗粒 - Google Patents

用于炎症成像的混合配体核/壳氧化铁纳米颗粒 Download PDF

Info

Publication number
CN102083471B
CN102083471B CN2009801083615A CN200980108361A CN102083471B CN 102083471 B CN102083471 B CN 102083471B CN 2009801083615 A CN2009801083615 A CN 2009801083615A CN 200980108361 A CN200980108361 A CN 200980108361A CN 102083471 B CN102083471 B CN 102083471B
Authority
CN
China
Prior art keywords
ligand
nanostructure
nanoparticle core
inorganic nanoparticle
nacl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2009801083615A
Other languages
English (en)
Chinese (zh)
Other versions
CN102083471A (zh
Inventor
B·格里蒙德
B·C·巴尔斯
T·恰基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Electric Co
Original Assignee
General Electric Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Electric Co filed Critical General Electric Co
Publication of CN102083471A publication Critical patent/CN102083471A/zh
Application granted granted Critical
Publication of CN102083471B publication Critical patent/CN102083471B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1836—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Polyethers (AREA)
CN2009801083615A 2008-03-05 2009-03-04 用于炎症成像的混合配体核/壳氧化铁纳米颗粒 Expired - Fee Related CN102083471B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/042,701 US20090226376A1 (en) 2008-03-05 2008-03-05 Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging
US12/042,701 2008-03-05
US12/042701 2008-03-05
PCT/EP2009/052523 WO2009109588A2 (en) 2008-03-05 2009-03-04 Mixed ligand core/shell iron oxide nanoparticles for inflammation imaging

Publications (2)

Publication Number Publication Date
CN102083471A CN102083471A (zh) 2011-06-01
CN102083471B true CN102083471B (zh) 2012-11-28

Family

ID=40940602

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801083615A Expired - Fee Related CN102083471B (zh) 2008-03-05 2009-03-04 用于炎症成像的混合配体核/壳氧化铁纳米颗粒

Country Status (5)

Country Link
US (1) US20090226376A1 (cg-RX-API-DMAC7.html)
EP (1) EP2247315A2 (cg-RX-API-DMAC7.html)
JP (1) JP2011516279A (cg-RX-API-DMAC7.html)
CN (1) CN102083471B (cg-RX-API-DMAC7.html)
WO (1) WO2009109588A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205155B2 (en) 2009-10-30 2015-12-08 General Electric Company Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents
EP2383374A1 (en) 2010-04-29 2011-11-02 BASF Corporation Nano-particles containing carbon and a ferromagnetic metal or alloy
EP2582400A4 (en) 2010-06-21 2016-05-25 Univ Washington Ct Commerciali MANIPULATED MULTIFUNCTIONAL MAGNETIC NANOPARTICLES FOR BIOMEDICINE
US9555136B2 (en) 2010-06-21 2017-01-31 University Of Washington Through Its Center For Commercialization Coated magnetic nanoparticles
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
WO2012174287A1 (en) * 2011-06-15 2012-12-20 The Board Of Regents Of The University Of Texas System Luminescent nanoparticle compositions
WO2013020701A2 (en) 2011-08-10 2013-02-14 Magforce Ag Agglomerating magnetic alkoxysilane-coated nanoparticles
US9017468B2 (en) 2012-04-25 2015-04-28 Hewlett-Packard Development Company, L.P. Colorant dispersion for an ink
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
KR102175449B1 (ko) * 2020-04-13 2020-11-06 주식회사 지티아이바이오사이언스 산화철/중원자-할로겐 화합물의 코어/쉘 구조 자성 나노입자
KR102175448B1 (ko) * 2020-04-13 2020-11-06 주식회사 지티아이바이오사이언스 중원자-할로겐 화합물이 도핑된 산화철 자성 나노입자
EP3895734B1 (en) 2020-04-13 2023-01-25 ZTI Biosciences Co., Ltd. Iron oxide magnetic particles comprising copper(i)halides
US20230232646A1 (en) * 2020-05-26 2023-07-20 Sharp Kabushiki Kaisha Light-emitting element and method of manufacturing light-emitting element
KR102488840B1 (ko) * 2021-06-23 2023-01-18 주식회사 지티아이바이오사이언스 산화철 자성 입자의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20060093555A1 (en) * 2004-04-02 2006-05-04 Torres Andrew S Imaging inflammatory conditions using superparamagnetic iron oxide agents
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
JP2007112679A (ja) * 2005-10-21 2007-05-10 Fujifilm Corp ナノ粒子及びその製造方法
WO2007070827A2 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797380B2 (en) * 2002-07-31 2004-09-28 General Electric Company Nanoparticle having an inorganic core
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US20050260137A1 (en) * 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US7462446B2 (en) * 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
DE102005056620A1 (de) * 2005-11-25 2007-06-06 Merck Patent Gmbh Amphiphile Silane
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083902A2 (en) * 2002-10-25 2004-09-30 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
US20060093555A1 (en) * 2004-04-02 2006-05-04 Torres Andrew S Imaging inflammatory conditions using superparamagnetic iron oxide agents
US20060105052A1 (en) * 2004-11-15 2006-05-18 Acar Havva Y Cationic nanoparticle having an inorganic core
JP2007112679A (ja) * 2005-10-21 2007-05-10 Fujifilm Corp ナノ粒子及びその製造方法
WO2007070827A2 (en) * 2005-12-15 2007-06-21 Bristol-Myers Squibb Pharma Company Contrast agents for myocardium perfusion imaging

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Randy De Palma et. al..《Surface modification of gamma-Fe2O3@SiO2 magnetic nanoparticles for the controlled interaction with biomolecules》.《Journal of Nanoscience and Nanotechnology》.2007,第7卷(第12期),第4626-4641页.
Randy De Palma et. al..《Surface modification of gamma-Fe2O3SiO2 magnetic nanoparticles for the controlled interaction with biomolecules》.《Journal of Nanoscience and Nanotechnology》.2007,第7卷(第12期),第4626-4641页. *

Also Published As

Publication number Publication date
CN102083471A (zh) 2011-06-01
US20090226376A1 (en) 2009-09-10
WO2009109588A9 (en) 2009-11-05
JP2011516279A (ja) 2011-05-26
WO2009109588A2 (en) 2009-09-11
WO2009109588A3 (en) 2010-07-22
EP2247315A2 (en) 2010-11-10

Similar Documents

Publication Publication Date Title
CN102083471B (zh) 用于炎症成像的混合配体核/壳氧化铁纳米颗粒
Dutta et al. Glutamic acid-coated Fe3O4 nanoparticles for tumor-targeted imaging and therapeutics
Xie et al. Iron oxide nanoparticle platform for biomedical applications
Gao et al. Tumor-penetrating peptide conjugated and doxorubicin loaded T1-T2 dual mode MRI contrast agents nanoparticles for tumor theranostics
Kim et al. A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle
Dave et al. Monodisperse magnetic nanoparticles for biodetection, imaging, and drug delivery: a versatile and evolving technology
Li et al. Superparamagnetic iron oxide nanoparticles as MRI contrast agents for non-invasive stem cell labeling and tracking
Dhavale et al. Monolayer grafting of aminosilane on magnetic nanoparticles: An efficient approach for targeted drug delivery system
Li et al. Facile one-pot synthesis of Fe3O4@ Au composite nanoparticles for dual-mode MR/CT imaging applications
Mekuria et al. Encapsulation of gadolinium oxide nanoparticle (Gd2O3) contrasting agents in PAMAM dendrimer templates for enhanced magnetic resonance imaging in vivo
Yan et al. Recent advances in multifunctional magnetic nanoparticles and applications to biomedical diagnosis and treatment
US20090280063A1 (en) Novel pei-peg graft copolymer coating of iron oxide nanoparticles for inflammation imaging
Wan et al. Self-assembled magnetic theranostic nanoparticles for highly sensitive MRI of minicircle DNA delivery
Zhang et al. Ultrasound-triggered BSA/SPION hybrid nanoclusters for liver-specific magnetic resonance imaging
Park et al. Surface design of Eu-doped iron oxide nanoparticles for tuning the magnetic relaxivity
Cai et al. Gadolinium-labeled ferritin nanoparticles as T 1 contrast agents for magnetic resonance imaging of tumors
Cormode et al. Inorganic nanocrystals as contrast agents in MRI: synthesis, coating and introduction of multifunctionality
Yang et al. Cross-linked magnetic nanoparticles with a biocompatible amide bond for cancer-targeted dual optical/magnetic resonance imaging
US20060093555A1 (en) Imaging inflammatory conditions using superparamagnetic iron oxide agents
CN104689338B (zh) 肿瘤靶向性酸敏前药与磁性纳米粒子偶联物的制法及应用
Jang et al. In vivo magnetic resonance and fluorescence dual imaging of tumor sites by using dye-doped silica-coated iron oxide nanoparticles
Huang et al. Chemical spacer design for engineering the relaxometric properties of core–shell structured rare earth nanoparticles
García-García et al. Multi-stimuli-responsive chitosan-functionalized magnetite/poly (ε-caprolactone) nanoparticles as theranostic platforms for combined tumor magnetic resonance imaging and chemotherapy
Liang et al. Gram-scale preparation of iron oxide nanoparticles with renal clearance properties for enhanced t 1-weighted magnetic resonance imaging
Stanicki et al. Impact of the chain length on the biodistribution profiles of PEGylated iron oxide nanoparticles: A multimodal imaging study

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121128

Termination date: 20140304